[Retroperitoneal lymph node dissection in testis cancer].
According to the rules of the European Interdisciplinary Consensus, retroperitoneal lymph node dissection (RPLND) will be indicated less frequently in patients with nonseminomatous testis cancer. In clinical stage I it will be done only exceptionally and in stage II A only in marker-negative patients. In all other stages RPLND will be recommended as residual tumor resection and additionally in "growing teratoma syndrome" and in rare situations as "desperation surgery." It will be difficult in future using the minor operations to enter the learning curve. Only advanced situations will have to be managed by urological surgeons. These operations will have to be performed predominantly in specialised centres.
Pottek
T
T
Abteilung Urologie, Bundeswehrkrankenhaus Hamburg. topot@t-online.de
D005062:European Union; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods* / Q000592:standards*; D008198:Lymph Nodes / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000556:secondary* / Q000601:surgery*; D010537:Peritoneum / Q000601:surgery; D010818:Practice Patterns, Physicians' / Q000592:standards*; D011300:Preoperative Care / Q000379:methods; D012186:Retroperitoneal Neoplasms / Q000556:secondary / Q000601:surgery; D018570:Risk Assessment; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000601:surgery*